The University of Iowa Viral Vector Core provides shuttle plasmids at no cost when intended for virus production. Material sent includes 10μl of plasmid. We suggest that you digest the plasmid after any amplification step and fully sequence the final plasmid to ensure there is no recombination.

Interested in Ordering?

Please view our ordering information for shuttle plasmids to learn how to register for an account, place orders for shuttle plasmids and make payment through our online system.

Plasmid Backbone

The pFIV3.2 backbone is based on the pVETL Backbone developed by Novartis/Chiron Technologies and modified by Patrick L. Sinn, PhD (University of Iowa) to improve safety and transgene expression:

  • The lentiviral central polypurine tract and the central termination sequence were added directly downstream of the gag sequence.
  • The Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element, WPRE, was added directly upstream of the rev response element, RRE.
  • The major splice donor and the initial gag sequence each have a mutation but the packaging signal was retained.
  • The FIV 3’LTR was rendered “self-inactivating” by deleting a portion of the U3 region.

G0654 pFIV3.2mcs

  • Cat: G0654
  • pFIV3.2 backbone, multiple cloning site.

G0655 pFIV3.2CMVmcs

  • Cat: G0655
  • pFIV3.2 backbone, CMV (Cytomegalovirus) Promoter, multiple cloning site.

G0656 pFIV3.2RSVmcs

  • Cat: G0656
  • pFIV3.2 backbone, RSV (Rous sarcoma virus) Promoter, multiple cloning site.

G0667 pFIV3.2CAGmcs

  • Cat: G0667
  • pFIV3.2 backbone, CAG (CMV enhancer fused to the chicken beta-actin promoter) Promoter, multiple cloning site.

G0356 pFIV3.2TREmcs

  • Cat: G0356
  • pFIV3.2 backbone, TRE tight (TET Response Element) Promoter, multiple cloning site.

G0668 pFIV3.2EF1amcs

  • Cat: G0668
  • pFIV3.2 backbone, Human elongation factor-1 alpha (EF1a) Promoter, multiple cloning site..

G0863 pFIV3.2PGKmcs

  • Cat: G0863
  • pFIV3.2 backbone, PGK(Phosphoglycerate kinase) Promoter, multiple cloning site.

G0752 pFIV3.2mcswtIRESeGFP

  • Cat: G0752
  • pFIV3.2 backbone, multiple cloning site, wild type IRES (internal ribosome entry site), eGFP (enhanced green fluorescent protein. The IRES-eGFP functions as a non-fusion protein reporter without the addition of a second promoter.

G0754 pFIV3.2CMVmcswtIRESeGFP

  • Cat: G0754
  • pFIV3.2 backbone, multiple cloning site, wild type IRES (internal ribosome entry site), eGFP (enhanced green fluorescent protein). The IRES-eGFP functions as a non-fusion protein reporter without the addition of a second promoter.

G0411 pFIV3.2mcseGFP

  • Cat: G0411
  • pFIV3.2 backbone, multiple cloning site, eGFP (enhanced green fluorescent protein).

G0859 pFIV3.2CMVmcwtIRESZeocin

  • Cat: G0859
  • pFIV3.2 backbone, CMV (Cytomegalovirus) Promoter, multiple cloning site, wild type IRES (internal ribosome entry site), Zeocin as a selectable marker.

G0913 pFIV3.2CMVmcwtIRESNeomycin

  • Cat: G0913
  • pFIV3.2 backbone, CMV (Cytomegalovirus) Promoter, multiple cloning site, wild type IRES (internal ribosome entry site), Neomycin as a selectable marker.

G0776 pFIV3.2CAGmcswtIRESeGFP

  • Cat: G0776
  • pFIV3.2 backbone, CAG (CMV enhancer fused to the chicken beta-actin promoter) Promoter, multiple cloning site, wild type IRES (internal ribosome entry site), eGFP.

G0860 pFIV3.2mcswtIRESZeocin

  • Cat: G0860
  • pFIV3.2 backbone, multiple cloning site, wild type IRES (internal ribosome entry site), Zeocin as a selectable marker.

G0432 pFIV3.2mcsCMVeGFP

  • Cat: G0432
  • pFIV3.2 backbone backbone, multiple cloning site, CMV (Cytomegalovirus) Promoter, eGFP (enhanced green fluorescent protein). Suitable for RNAi cassettes.

G0973 pFIV3.2mU6shSafeCMVeGFP

  • Cat: G0973
  • pFIV3.2 backbone backbone, Mouse U6 Promoter driving a scrambled shRNA control shSafe cassette, CMV (Cytomegalovirus) Promoter, eGFP (enhanced green fluorescent protein).
  • Please reference: Boudreau, R. L., et al. (2011). "Rational Design of Therapeutic siRNAs: Minimizing Off-targeting Potential to Improve the Safety of RNAi Therapy for Huntington's Disease." Mol Ther 19(12): 2169-2177.